Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Novo Nordisk | NVO | NYSE | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 125.79 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 125.79 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 75.56 - 138.28 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 125.79 | USD |
Novo Nordisk (NVO) Options Flow Summary
Novo Nordisk Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 556.99B | 4.51B | - | 232.26B | 83.68B | 18.56 | 6.66 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Novo Nordisk News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NVO Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 123.55 | 128.76 | 122.46 | 125.46 | 3,850,506 | 2.24 | 1.81% |
| 1 Month | 129.11 | 129.11 | 121.79 | 125.31 | 3,514,840 | -3.32 | -2.57% |
| 3 Months | 113.76 | 138.28 | 113.24 | 126.11 | 4,888,320 | 12.03 | 10.57% |
| 6 Months | 96.00 | 138.28 | 92.94 | 114.38 | 4,591,396 | 29.79 | 31.03% |
| 1 Year | 82.83 | 138.28 | 75.56 | 106.38 | 3,438,892 | 42.96 | 51.87% |
| 3 Years | 36.875 | 138.28 | 36.6225 | 84.54 | 2,022,710 | 88.92 | 241.13% |
| 5 Years | 24.49 | 138.28 | 23.00 | 67.40 | 1,768,280 | 101.30 | 413.64% |
Novo Nordisk Description
| Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders. |
